Phase 3 Readout
NYMXF: Phase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua
October 29, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 29, 2026
- Company
- NYMOX PHARMACEUTICAL CORP (NYMXF)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua
- Indication
- Schizophrenia